Lawrence Korducki

Tiotropium and olodaterol fixed-dose combination <i>versus</i> mono-components in COPD (GOLD 2–4)

Roland Buhl, François Maltais, R Abrahams et al. · European Respiratory Journal · 2015 · 322 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +17

Effect of Bronchodilation, Exercise Training, and Behavior Modification on Symptoms and Physical Activity in Chronic Obstructive Pulmonary Disease

Thierry Troosters, François Maltais, Nancy Kline Leidy et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 101 citations

Medicine, Pharmacotherapy, Rehabilitation Medicine +17

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat&amp;reg; versus placebo and formoterol twice daily in patients with GOLD 2&amp;ndash;4 COPD: results from two replicate 48-week studies

Andrea Koch, Emílio Pizzichini, Alan Hamilton et al. · International Journal of COPD · 2014 · 95 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease

J.A. van Noord, J.J. Smeets, Frank L. Custers et al. · European Respiratory Journal · 2002 · 91 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of olodaterol once daily delivered via Respimat&amp;reg; in patients with GOLD 2&amp;ndash;4 COPD: results from two replicate 48-week studies

Gary T. Ferguson, Gregory Feldman, Peter Hofbauer et al. · International Journal of COPD · 2014 · 71 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17